Post Marketing Information DHCPL 23/07/2019 Risk of non-melanoma skin cancer associated with use of hydrochlorothiazide DHCPL 03/12/2018 Hydrochlorothiazide: Association with non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) [Sanofi] DHCPL 21/11/2018 Hydrochlorothiazide: Increased risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) DHCPL 14/11/2018 Hydrochlorothiazide: Association with non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Hydrochlorothiazide 12.5 mg + Telmisartan 40 mg National Heart Centre National University Hospital Tablet, Hydrochlorothiazide 12.5 mg + Telmisartan 80 mg National Heart Centre National University Hospital
ORAL Select a brand starting with the letter: M T MICARDIS PLUS TABLET 40/12.5 MG [SIN12394P] MICARDIS PLUS TABLET 80/12.5 MG [SIN12395P] TELMOTENS PLUS TABLETS 40 MG/ 12.5 MG [SIN14657P] TELMOTENS PLUS TABLETS 80 MG/ 12.5 MG [SIN14656P] TELSTAN-H 40/12.5 TABLET 40 MG/12.5 MG [SIN14603P] See all TELSTAN-H 80/12.5 TABLET 80 MG/12.5 MG [SIN14602P] TELSTAN-H 80/25 TABLET 80MG/25MG [SIN15091P] TOLUCOMBI TABLET 40MG/12.5MG [SIN15617P] TOLUCOMBI TABLET 80MG/12.5MG [SIN15616P]